Signing of Term Sheet with Hidrigin

This is a cautious, early-stage deal with many hurdles and little immediate investor impact.

What the company is saying

Clean Power Hydrogen plc (AIM:CPH2) is positioning this announcement as a strategic milestone, highlighting the execution of a binding term sheet with Lisheen H2 Energy Park Limited (Hidrigin) for a £750,000 convertible loan note (CLN). The company wants investors to believe this is a meaningful step toward a broader partnership, emphasizing the potential for joint technology development and future manufacturing collaboration. The language is precise and transactional, focusing on the mechanics of the CLN—such as the 10% interest rate, 46% conversion discount, and security over company assets—rather than making grand claims about future revenues or market dominance. Prominently, the announcement stresses the exclusivity period (nine months) for negotiating a strategic partnership and the conditional nature of the CLN, which depends on CPH2 raising at least £3 million in new equity. What is buried or omitted is any discussion of current financial health, operational performance, or concrete timelines for revenue generation or project delivery. The tone is neutral and measured, with management avoiding promotional language and explicitly noting that there is no certainty definitive agreements will be reached. Notable individuals named include Eric Whelan (CEO of Hidrigin) and Richard Scott (CEO Elect of CPH2), but their involvement is procedural rather than a signal of external validation or institutional capital. This narrative fits a broader investor relations strategy of signaling progress and partnership potential without overcommitting or overstating near-term impact. Compared to typical small-cap announcements, the messaging here is more restrained, with no discernible shift toward hype or aggressive forward guidance.

What the data suggests

The disclosed numbers are limited to the transaction itself: a £750,000 CLN at 10% interest, convertible at a 46% discount to a future equity raise (with a cap of 3.7p and a floor of 1p per share), and conditional on CPH2 raising at least £3 million in new equity. There are no revenue, profit, cash flow, or operational metrics provided, so the financial trajectory of the company cannot be assessed from this announcement. The only cash movement is the conversion of a previously received £750,000 interim payment from Hidrigin into the CLN, meaning no new cash is entering the business at this stage. There is a clear gap between the implied strategic significance of the deal and the actual financial impact, which is currently neutral—no new funds, no immediate dilution, and no operational milestone achieved. Prior targets or guidance are not referenced, and there is no way to determine if the company is meeting, missing, or exceeding its own benchmarks. The quality of disclosure is adequate for understanding the transaction terms but wholly insufficient for evaluating the company’s financial health or prospects. An independent analyst, looking only at the numbers, would conclude that this is a procedural step with no immediate financial benefit or risk, and that the company remains highly dependent on future fundraising and successful negotiation of further agreements.

Analysis

The announcement is primarily a factual disclosure of a binding term sheet for a convertible loan note and outlines the associated terms and conditions. The language is measured and avoids promotional or exaggerated claims, focusing on the mechanics of the transaction rather than projecting future success or benefits. While there are some forward-looking statements regarding the intention to negotiate a strategic partnership and potential joint IP development, these are clearly identified as subject to further negotiation and are not presented as realised outcomes. The majority of key claims are either realised (execution of the term sheet, receipt of interim payment) or conditional on specific, disclosed events (future fundraising). There is no evidence of narrative inflation or overstatement, and the announcement explicitly notes the uncertainty of future agreements. No large capital outlay is paired with long-dated, uncertain returns in this disclosure.

Risk flags

• ●Execution risk is high: The entire transaction is conditional on CPH2 raising at least £3 million in new equity, which may not materialize given current market conditions or company fundamentals. If the fundraising fails, the CLN and associated partnership will not proceed, leaving the company with no new capital or strategic progress.
• ●Operational risk is significant: The announcement provides no information on current production, sales, or operational milestones, making it impossible to assess whether the company can deliver on its technology or partnership promises. This lack of operational transparency increases uncertainty for investors.
• ●Disclosure risk is material: The company omits all financial performance data—no revenue, profit, cash position, or burn rate is disclosed. This lack of visibility into the company’s financial health makes it difficult for investors to gauge solvency or runway.
• ●Timeline risk is pronounced: The key benefits of the deal (strategic partnership, joint IP, manufacturing collaboration) are all forward-looking and subject to lengthy negotiation periods, with a long stop date more than two years away. Investors face a long wait before any value may be realized, with no guarantee of success.
• ●Pattern risk: The announcement is purely transactional and does not reference any history of successful execution or delivery on prior deals. Without evidence of follow-through, there is a risk that this deal, like others, may not progress beyond the term sheet stage.
• ●Financial risk: The CLN is secured by a floating charge over company assets, which could put existing shareholders at risk of subordination if the company encounters financial distress. The terms favor the lender (Hidrigin) with a deep conversion discount and security, while offering little immediate upside to equity holders.
• ●Forward-looking risk: The majority of the announcement’s value proposition is based on future intentions—negotiating a partnership, developing joint IP, and transitioning to an IP-led model. None of these are realized, and the company explicitly states there is no certainty of completion.
• ●Geographic and counterparty risk: The deal involves multiple jurisdictions (Ireland, UK, North America) and relies on the continued engagement of Hidrigin and its engineering partner. Any change in regulatory, market, or counterparty circumstances could derail the process.

Bottom line

For investors, this announcement is best viewed as a procedural update rather than a catalyst for immediate action. The execution of a binding term sheet for a £750,000 convertible loan note is a necessary but not sufficient step toward a broader partnership with Hidrigin. The transaction brings no new cash into CPH2 at this stage, as it merely converts a previously received interim payment into a CLN, and is entirely conditional on a future £3 million equity raise. The company’s narrative is credible in that it avoids hype and clearly states the conditional and uncertain nature of the deal, but it offers no evidence of operational progress or financial improvement. No notable institutional investors are participating—Hidrigin is a commercial counterparty, not a financial backer, and the involvement of named executives is routine rather than a signal of external validation. To change this assessment, the company would need to disclose successful completion of the equity raise, execution of definitive partnership agreements, or tangible operational milestones such as revenue from joint projects. Key metrics to watch in the next reporting period include cash position, fundraising progress, and any updates on the exclusivity or partnership negotiations. Investors should treat this as a signal to monitor rather than to act on—there is no immediate value creation, and the risks of non-completion and dilution remain high. The single most important takeaway is that while the company is making incremental progress toward a strategic partnership, the path to value realization is long, uncertain, and fraught with execution risk.

Announcement summary

(AIM: CPH2) Clean Power Hydrogen plc announced that it has executed a binding term sheet with Lisheen H2 Energy Park Limited (Hidrigin) for a £750,000 convertible loan note accruing interest at 10 per cent. per annum. The CLN is conditional upon the completion of an equity fundraise by CPH2 of £3 million or more by way of an issue of Ordinary Shares. The CLN shall convert at a 46% discount to the price applicable to the relevant conversion event, subject to a gross pricing cap of 3.7 pence per Ordinary Share and a net floor price of 1 pence per Ordinary Share. The £750,000 is to be funded by converting a £750,000 interim payment previously received by CPH2 from Hidrigin in connection with a stage milestone under an MFE220 electrolyser sales contract. The CLN is secured by way of a first ranking floating charge over the assets and undertakings of the Company. The Company and Hidrigin will, within 28 days of the Term Sheet, enter into an exclusivity arrangement lasting nine months to negotiate and complete a Strategic Partnership and Manufacturing and Technology Development Agreement. The binding Term Sheet has a long stop date of 31 July 2026 and there can be no certainty that definitive documentation will be entered into.

Disagree with this article?